<DOC>
	<DOCNO>NCT00781859</DOCNO>
	<brief_summary>The objective trial evaluate safety efficacy intravitreal microplasmin 125µg dose subject wiht focal vitreomacular adhesion .</brief_summary>
	<brief_title>Trial Microplasmin Intravitreal Injection Non-surgical Treatment Focal Vitreomacular Adhesion . The MIVI-TRUST ( TG-MV-006 ) Trial .</brief_title>
	<detailed_description />
	<mesh_term>Tissue Adhesions</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<criteria>Presence focal vitreomacular adhesion ( i.e. , central vitreal adhesion within 6mm Optical Coherence Tomography ( OCT ) field surround elevation posterior vitreous cortex ) opinion Investigator relate decreased visual function ( metamorphopsia , decrease visual acuity , visual complaint ) Any evidence proliferative retinopathy ( include Proliferative Diabetic Retinopathy ( PDR ) ischemic retinopathy involve vitreoretinal vascular proliferation ) exudative AgeRelated Macular Degeneration ( AMD ) retinal vein occlusion study eye . Subjects vitreous hemorrhage vitreous opacification precludes either follow : visualization posterior pole visual inspection OR adequate assessment macula either OCT and/or fluorescein angiogram study eye . Subjects macular hole diameter &gt; 400 μm study eye . Aphakia study eye . High myopia ( 8D ) study eye ( unless prior cataract extraction refractive surgery make refraction assessment unreliable myopia severity approximation , case axial length &gt; 28 mm exclusion ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>